Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

ASCO 2024

Genitourinary Cancer

PSMAfore: ¹⁷⁷Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers

Gastrointestinal Cancer

Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study

Clin Cancer Res

Slater S, Bryant A, Aresu M, Begum R, Chen HC, Peckitt C, Lazaro-Alcausi R, Carter P, Anandappa G, Khakoo S, Melcher L, Potter V, Marti Marti F, Huang J, Branagan G, George N, Abulafi M, Duff S, Raja A, Gupta A, West N, Bucheit L, Rich T, Chau I, Cunningham D, Starling N

doi: 10.1158/1078-0432.CCR-24-0226

SABCS 2024

Breast Cancer

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

Gastrointestinal Cancer

The Landscape of Circulating Tumor DNA (ctDNA) in Appendiceal Adenocarcinoma

Clin Cancer Res

White MG, Zeineddine MA, Fallon EA, Zeineddine FA, Dansby J, Chowdhury S, Hornstein N, Yousef A, Yousef M, Bhutiani N, Gu Y, Kee B, Dasari A, Overman MJ, Raghav K, Kopetz S, Uppal A, Taggart M, Newhook T, Fournier K, Helmink B, Drusbosky LM, Shen JP

doi: 10.1158/1078-0432.CCR-24-2474

ASCO 2024

Breast Cancer

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Further Publications

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

J Clin Oncol

Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, Komatsu Y, Esaki T, Sakai D, Doi A, Kajiwara T, Ono H, Asano M, Hirano N, Odegaard J, Fujii S, Nomura S, Bando H, Sato A, Yoshino T, Nakamura Y

doi: 10.1200/JCO.23.02626

Central Nervous System Tumors

Streamlined intraoperative brain tumor classification and molecular subtyping in stereotactic biopsies using stimulated Raman histology and deep learning

Clin Cancer Res

Reinecke D, Ruess D, Meissner AK, Fürtjes G, von Spreckelsen N, Ion-Margineau A, Khalid F, Blau T, Stehle T, Al-Shughri A, Büttner R, Goldbrunner R, Ruge MI, Neuschmelting V

doi: 10.1158/1078-0432.CCR-23-3842

Genitourinary Cancer

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer

JAMA Oncol

Hamm CA, Asbach P, Pöhlmann A, Schoots IG, Kasivisvanathan V, Henkel TO, Johannsen M, Speck T, Baur ADJ, Haas M, Collettini F, Penzkofer T, Savic LJ, Konietschke F, Weißbach L, Hamm B, König F, Cash H

doi: 10.1001/jamaoncol.2024.5497

Related content

PSMAfore: 177Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers

Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study

CAPItello-291: Comparable prevalence of PIK3CA/AKT1/PTEN alterations in primary and recurrent tumors in HR-positive, HER2-negative breast cancer

The Landscape of Circulating Tumor DNA (ctDNA) in Appendiceal Adenocarcinoma

monarchE: ctDNA detection is highly prognostic of worse clinical outcomes in patients with HR-positive, HER2-negative, lymph node-positive early breast cancer

Results of TRODELVY® real-world data

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

Streamlined intraoperative brain tumor classification and molecular subtyping in stereotactic biopsies using stimulated Raman histology and deep learning

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer

PSMAfore: ¹⁷⁷Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers

Results of TRODELVY^® real-world data